How Practices Build a Six-Figure Peptide Revenue Line (Without Billing Insurance)

A peptide line is a cash-pay program. Patients pay the practice directly, the practice buys at wholesale and sells at retail, and no insurance company sits between the two. The revenue builds in three layers: the initial protocol sale, the monthly reorder, and the multi-product stack. Practices that run peptides as a structured program, with protocols and scheduled follow-up, are the ones that turn it into a six-figure line. Practices that put a product on a shelf and wait do not. Here is how the model actually works.

Why Does Cash-Pay Change the Economics?

Because every dollar is collected at the point of sale, and the spread between wholesale cost and retail price stays in the practice. There is no fee schedule deciding what the service is worth, no billing staff working claims, no waiting 45 days for reimbursement, and no clawbacks.

Compare that to almost everything else a practice does:

• No reimbursement risk. The patient pays when they pick up the product. There is nothing to appeal and nothing to write off.
• No added billing overhead. A peptide program does not add a single claim to your billing team's queue.
• Pricing control. The practice sets retail pricing based on the value of the program, not on what a payer allows.

This is the same reason aesthetics, memberships, and supplements became practice staples. Peptides follow the same cash-pay logic, with one advantage: patient demand for the category is already being created by GLP-1 medications in the wider market.

Where Does Peptide Revenue Actually Come From?

Three layers, and each one builds on the last.

1. 1The initial protocol sale. A patient starts a structured program, typically anchored in metabolic or recovery support, because those are the questions patients are already asking. This is the entry transaction.
2. 2Monthly reorders. Formulated products are consumed on a monthly cadence, and a patient on a 90-day protocol reorders as part of the plan. This is where the line stops being episodic and starts compounding. Twenty patients reordering monthly is a fundamentally different business than twenty one-time sales.
3. 3Multi-product stacks. The same patient usually has needs across two or three of the five peptide categories patients ask about. A weight patient adds recovery support. A longevity patient adds cognitive support. A topical serum layers onto nearly any protocol. Stacks raise revenue per patient without requiring a single new patient.

The practices that reach six figures are the ones that treat all three layers as deliberate steps in a program, with follow-up visits that check progress and set up the next stage.

What Does It Cost to Launch?

Less than almost any other service line a practice can add. There is no equipment purchase, no room buildout, and no new licensure category. The real inputs are:

• Initial wholesale inventory. A starting order sized to your first patient cohort, not a warehouse commitment.
• Sample kits and one-week trials. Low-cost entry points that lower patient resistance and convert into full protocols.
• Staff time. The Clinical Operator's Manual, the on-demand training video library, and ready-made compliance templates exist so that training is measured in days, not months.

Because the launch inputs are small, the break-even point arrives early, and everything after it is margin on a cash-pay product.

How Should a Practice Price Peptides?

Price the program, not the pill. Patients are not buying a bottle, they are buying a supervised protocol with clinical oversight, education, and follow-up. That framing supports healthy retail pricing and it is also simply accurate.

Three practical rules:

• Use the suggested retail guidance. Every AgeREcode product comes with suggested retail pricing so you are not guessing at what the market bears.
• Bundle where it makes sense. A 90-day program price that includes product plus check-ins outperforms piecemeal pricing.
• Lead with the one-week trial. A small yes today becomes a protocol next week. Trials exist to remove the entry barrier.

Specific product costs, suggested retail, and margin projections are in the member pricing guide. Request wholesale access to review the full numbers for your practice.

What Do the First 90 Days Look Like?

A realistic ramp looks like this:

• Weeks 1 to 2: Set up. Staff completes training, consent and intake templates go into the workflow, and the first inventory order arrives.
• Weeks 3 to 6: Introduce. Start with existing patients, especially current or former GLP-1 patients, because they already trust the category. Use sample kits and one-week trials as the ask.
• Weeks 7 to 12: Compound. Follow-up visits convert trials into protocols, protocols into reorders, and single products into stacks. This is where the recurring layer forms.

Track three numbers from day one: attach rate (what share of eligible patients start), reorder rate (what share come back monthly), and revenue per active patient per month. Those three tell you whether you have a program or a shelf.

Frequently Asked Questions